RU2066180C1 - Agent for tooth cleansing - Google Patents

Abstract

FIELD: stomatology. SUBSTANCE: oral composition contains polyphosphate agent preventing concrement formation, for example, tetraalkaline metal pyrophosphate and compatible antibacterial agent preventing tooth deposit formation. Preventing agent is water-insoluble noncationic antibacterial agent, for example, 2,4,4'-trichloro-2'-hydroxydiphenyl ether (triclosan). Antibacterial agent shows enhanced effect due to its increased absorption and retention on the mouth cavity surface. EFFECT: enhanced effectiveness of agent.

Description

 The invention relates to antibacterial, preventing the formation of plaque and calculi of the oral (oral) composition. More specifically, the invention relates to an oral composition containing a polyphosphate, which prevents the formation of calculus (i.e., tartar) agents and a joint antibacterial agent effective in preventing the formation of plaque, the effectiveness of which is optimized by the presence of an agent that enhances the effect of the antibacterial agent by increasing and holding the antibacterial agent on the oral surfaces.

 In US Pat. N 4,627,977 to Gabbar et al. 4515772 at Ms Parran et al. and 4323551 in the name of Parran describe oral compositions comprising various polyphosphate compounds. In the patent for the name Gabbar et al. To inhibit the formation of calculi, a linear molecularly dehydrated polyphosphate salt is used in combination with a source of fluoride ions and a linear synthetic polycarboxylate. In the pending European Patent Application 89,200,710.5, the prevention of calculus formation is optimized by using a reduced amount of linear molecularly dehydrated polyphosphate salt in combination with a source of fluoride ions and an increased amount of synthetic linear polymeric polycarboxylate.

 In patents in the name of Parran et al. and in the name of Parran, water-soluble di-alkali metal pyrophosphate as such is mixed with tetra-alkali metal pyrophosphate.

 Oral compositions inhibiting the formation of calculi on the surface of the teeth are highly desirable since tartar is one of the factors causing periodontitis. That is, reducing the formation of tartar serves as rotting of the oral cavity.

 Plaque is a precursor to tartar. But unlike tartar, plaque can form on any part of the tooth surface, including at the edge of the gum. That is, in addition to the fact that invisible plaque is responsible for the occurrence of gingivitis.

 Thus, it is highly desirable to include, in oral compositions containing an anti-calculus preparation, antimicrobial agents for which there is a known ability to reduce plaque formation. This approach is actually described in US patent N 4022550 in the name of Vinson c et al. in which the compound giving zinc ions, as a means of preventing the formation of calculi, is mixed with an antibacterial agent that effectively inhibits the growth of plaque bacteria. A variety of antibacterial agents are provided along with zinc compounds, including cationic materials such as guanides and quaternary ammonium compounds, as well as non-cationic compounds such as halogenated salicylanilides and halogenated hydroxydiphenyl ethers.

 To date, cationic antibacterial agents such as chlorhexidine, benzonium chloride and cetylpyridinium chloride have been the subject of enhanced research as antibacterial plaque-preventing agents. However, despite their use in combination with zinc anti-calculus agents, they are ineffective when used with anionic substances such as polyphosphate anti-calculus agents. Such inefficiency can be considered extremely unexpected, since polyphosphates are chelating agents, and the chelating effect has been found to increase the effectiveness of cationic antibacterial agents (see, for example, Disinfection, Sterilization and Preservation, 2nd ed. BLack, 1977, p. . 915 and "Inhibition and destruction of microbial cells", Hugo, 1971, p. 215). Indeed, the quaternary ammonium compound is present in a pyrophosphate-containing mouthwash preventive agent containing pyrophosphate of US Pat. No. 4,325,251 to Parran, and bisbiguanide in the anti-calculus oral composition of US Pat. No. 4,525,772 to Parran is proposed. with sotr.

 Due to the unexpected incompatibility of cationic antibacterial agents with polyphosphates present as anti-calculus agents, it is difficult to expect efficacy from other antibacterial agents.

 An advantage of the present invention is that certain antibacterial agents are effective in preventing calculus formation of oral compositions containing a linear molecularly dehydrated polyphosphate salt, a fluoride ion source and the aforementioned antibacterial agent for inhibiting plaque formation.

 Another advantage of the present invention is that it provides a composition effective in terms of reducing the formation of calculi and optimizing the prevention of plaque formation.

 And another advantage of the invention is that it provides an anti-calculus and plaque-forming oral composition that is effective in reducing the likelihood of gingivitis.

 Additional advantages of the invention will become apparent upon consideration of the following description.

 In accordance with some of its aspects, the invention relates to an oral composition containing an orally acceptable carrier, effectively preventing the formation of calculi, the amount of material, including 0.1 to 3 wt. at least one linear molecularly dehydrated polyphosphate salt as an anti-calculus agent, effectively preventing dental plaque formation of an amount of a substantially non-water-insoluble non-cationic antibacterial agent, and preferably up to 4 wt. an agent that enhances the effect of the antibacterial agent, which enhances the intake and retention of the antibacterial agent on the oral surfaces, where, as a rule, the ratio by weight of the polyphosphate ion to the enhancing effect of the antibacterial agent is in the range from more than 0.72: 1 to less than 4: 1, for example from 1: 1 to 3.5: 1, especially from 1.6: 1 to 2.7: 1, preferably from 1.7: 1 to 2.3: 1, and most preferably from 1.9: 1 up to 2: 1. For example, in the case of using 2% tetrasodium pyrophosphate (TNAF) (forms 1.3% pyrophosphate ion) with 2.5% of an agent that enhances the effect of the antibacterial agent, this provides a highly desirable ratio by weight of components of 1.9: 1 .

Typical examples of antibacterial agents that are particularly desirable in terms of efficacy for preventing plaque formation, safety, and formulation preparation include:
Halogenated diphenyl ethers
2 ', 4,4'-trichloro-2-hydroxydiphenyl ether (triclosan),
2,2'-dihydroxy-5,5'-dibromodiphenyl ether,
Halogenated salicylanilides
4 ', 5-diromsalicylanilide,
3,4 ', 5-tribromosalicylanilide,
2,3,3 ', 5-tetrachlorosalicylanilide,
3,3,3'5-tetrachlorosalicylanilide,
3,5-dibromo-3'-trifluoromethylsalicylanilide (photophene),
5-n-octanoyl-3'-trifluoromethylsalicylanilide,
3,5-dibromo-4'-trifluoromethylsalicylanilide,
Benzoic acid esters
p-hydroxybenzoic acid methyl ester,
p-hydroxybenzoic acid ethyl ester,
p-hydroxybenzoic acid propyl ester,
p-hydroxybenzoic acid butyl ether,
Halogenated carbanilides
3,4,4'-trichlorocarbonylanilide,
3-trifluoromethyl-4,4'-dichlorocarbonylidene,
3,3,4'-trichlorocarbonylanilide,
phenolic compounds (including phenol and its homologs, mono- and polyalkylphenols, substituted in the aromatic nucleus with a halogen (for example, Е, Сl, В,) phenols, resorcinol and catechin and their derivatives, as well as biophenol compounds). Such phenolic compounds, among others, include:
Phenol and its homologues
phenol,
2-methylphenol,
3-methylphenol
4-methylphenol
4-ethylphenol,
2,4-dimethylphenol,
2,5-dimethylphenol,
3,4-dimethylphenol,
2,6-dimethylphenol,
4-n-propylphenol,
4-n-butylphenol,
4-n-amylphenol,
4-tert-amylphenol,
4-n-hexylphenol,
4-n-heptylphenol,
2-methoxy-4- (2-propenyl) phenol) (eugenol),
2-isopropyl-5-methylphenol (thymol),
Mono- and polyalkyl-, aralkyl halophenols
methyl p-chlorophenol,
ethyl p-chlorophenol,
n-propyl-p-chlorophenol,
n-butyl-p-chlorophenol,
n-amyl-p-chlorophenol,
fluoro-amyl-p-chlorophenol,
n-hexyl-p-chlorophenol,
cyclohexi-p-chlorophenol,
n-heptyl-p-chlorophenol,
n-octyl-p-chlorophenol,
o-chlorophenol,
methyl o-chlorophenol,
ethyl o-chlorophenol,
n-propyl-o-chlorophenol,
n-butyl-o-chlorophenol,
n-amyl-o-chlorophenol,
tert-amyl-o-chlorophenol,
n-hexyl-o-chlorophenol,
n-heptyl-o-chlorophenol,
p-chlorophenol,
o-phenyl-p-chlorophenol,
o-benzyl-m-methyl-p-chlorophenol,
o-benzyl-m, m-dimethyl-p-chlorophenol,
o-phenethyl-p-chlorophenol,
o-phenethyl-m-methyl-p-chlorophenol,
3-methyl-p-chlorophenol,
3,5-dimethyl-p-chlorophenol,
6-ethyl-3-methyl-p-chlorophenol,
6-n-propyl-3-methyl-p-chlorophenol,
6-isopropyl-3-methyl-p-chlorophenol,
2-ethyl-3,5-dimethyl-p-chlorophenol,
6-sec-butyl-3-methyl-p-chlorophenol,
2-isopropyl-3,5-dimethyl-p-chlorophenol,
6-diethylmethyl-3-methyl-p-chlorophenol,
6-isopropyl-2-ethyl-3-methyl-p-chlorophenol,
2-sec-amyl-3,5-dimethyl-p-chlorophenol,
2-diethylmethyl-3,5-dimethyl-p-chlorophenol,
6-sec-octyl-3-methyl-p-chlorophenol,
p-bromophenol,
methyl p-bromophenol,
ethyl p-bromophenol,
n-propyl-p-bromophenol,
n-butyl-p-bromophenol,
n-amyl-p-bromophenol,
fluoro-amyl-p-bromophenol,
n-hexyl-p-bromophenol,
cyclohexyl-p-bromophenol,
o-bromophenol
o-bromophenol
tert-amyl-o-bromophenol,
n-hexyl-o-bromophenol,
n-propyl-m, m-dimethyl-o-bromophenol,
4-chloro-2-methylphenol,
2-phenylphenol,
4-chloro-3-methylphenol,
4-chloro-3,5-dimethylphenol,
2,4-dichloro-3,5-dimethylphenol,
3,4,5,6-tetrabromo-2-methylphenol,
5-methyl-2-pentylphenol,
4-isopropyl-3-methylphenol,
5-chloro-2-hydroxyphenylmethane,
Resorcinol and its derivatives
resorcinol
methylresorcinol
ethylresorcinol
n-propylresorcinol,
n-butylresorcinol,
n-amylresorcinol,
n-hexylresorcinol
n-heptylresorcinol,
n-octylresorcinol,
n-nonylresorcinol,
phenylresorcinol
benzylresorcinol,
phenylethylresorcinol
phenylpropylresorcinol,
i-chlorobenzylresorcinol,
5-chloro-2,4-dihydroxydiphenylmethane,
4'-chloro-2,4-dihydroxyphenylmethane,
5-bromo-2,4-dihydroxyphenylmethane,
4'-bromo-2,4-dihydroxyphenylmethane,
Bisphenol compounds
Bisphenol A
2,2'-methylenebis (4-chlorophenol),
2,2'-methylenebis (3,4,6-trichlorophenol) (hexachlorophenol),
2,2'-methylenebis (4-chloro-6-bromophenol),
bis (2-hydroxy-3,5-dichlorophenyl) sulfide,
bis (2-hydroxy-5-chlorobenzyl) sulfide.

 An antibacterial agent is present in the oral composition in an amount effective to prevent plaque formation, usually 0.01 -5 wt.%, Preferably 0.03 -1 wt. and very preferably 0.25 to 0.5 wt. and most preferably 0.25 to 0.35 wt. The antibacterial agent is essentially insoluble in water, i.e. its solubility in water at 25 C is less than 1 wt. and maybe even less than 0.1%. In the presence of ionizable groups, solubility is determined at pH values at which ionization does not occur.

 Recommended halogenated diphenyl ethers include triclosan. Recommended phenolic compounds include phenol, 2,2'-methylenebis (4-chloro-6-bromophenol), thymol and eugenol. Triclosan is the most recommended antibacterial anti-plaque inhibitor. Triclosan is described in the aforementioned US Pat. No. 4,022,880 as an antibacterial agent in combination with a stone formation preventing agent giving zinc ions, as well as in the description of the German Federal Patent No. 3,532,860 in combination with a copper compound. Triclosan is also used to prevent plaque formation in a dentifrice composition containing a layered liquid crystal surface-active phase with a layer spacing of less than 6 nm, which may also include zinc salt (see published European patent application No. 0161898 for Lane c al.), and in a dentifrice composition containing zinc citrate trihydrate (see published European Patent Application No. 0161899 in the name of Saxbon).

The linear molecularly dehydrated polyphosphate layers used in the present invention are well known. As a rule, they are used in the form of fully or partially neutralized water-soluble alkali metal (for example, potassium, but preferably sodium) or ammonium salts or any mixtures thereof. Representative examples include sodium hexametaphosphate, sodium tripolyphosphate, disodium acid, trisodium monoacid and tetrasodium pyrophosphates, the corresponding potassium salts, etc. The linear polyphosphates are represented by the formula (NaPO ₃ ) _n , where n 2 125. In the present invention, polyphosphates are used in oral compositions in approximate amounts weight 1 3% usually 1 2.5% more usually 1.5 2% When n is equal to at least 3 formula (NaPO ₃ ) _n , polyphosphate in nature is a glassy substance.

 Particularly desirable anti-calculus agents include tetra-alkali metal pyrophosphates, including mixtures thereof, for example tetrasodium pyrophosphate, tetracal pyrophosphate, and mixtures thereof. Thus, the oral composition may contain a polyphosphate calculus-preventing agent that is substantially free of tetrasodium pyrophosphate or substantially free of the combination of tetracal pyrophosphate with tetrasodium pyrophosphate, where the ratio of potassium pyrophosphate to sodium pyrophosphate is 3: 1 or more 3: 1. An anti-calculus preparation containing about 2% by weight of the tetrasodium pyrophosphate oral agent is particularly effective.

 The antimicrobial enhancing agent (UAA), which enhances the uptake and retention of the antimicrobial on the oral surfaces, is used in amounts effective from the point of view of such effort in the concentration range on the oral composition of 0.5-4%, preferably 0.1 3% more preferably 0.5 to 2.5 wt.

 AAA can be a simple compound, preferably a polymerizable monomer, more preferably a polymer, the latter term being purely generic, including, for example, oligomers, homopolymers, graft copolymers, crosslinked polymers, copolymers, and the like. AAA can be natural or synthetic and insoluble in water, or preferably soluble in water (saliva) or swellable), hydratable, capable of forming a hydrogel). The average molecular weight of the UAA is 100,000,000, preferably 1,000 to 1,000,000, more preferably 2,000 or 25,000, 250,000 or 500,000.

The AAA typically has at least one income enhancing group, which is preferably an acidic group, such as a sulfonic, phosphonic, or more preferably a phosphonic or carbonic salt or a salt thereof, for example an alkali metal or ammonium salt, and at least one organic retention enhancing group, preferably a series both enhancing the intake and enhancing the retention of the groups, the latter preferably corresponding to the formula - (X) _n -R, where X O, N, S, SO, SO ₂ , P, PO, Si, etc. R is hydrophobic alkyl, alkenyl, acyl, aryl, alkaryl, aralkyl, heterocycle or their inertly substituted derivatives and n 0 or n ≥1. The above term “inertly substituted derivatives” includes a type of substituents y, R that are usually non-hydrophilic and do not significantly affect the target functions of the UAA to enhance the intake and retention of the antibacterial agent on the oral surfaces, and such substituents include a halogen, for example, Cl, Br, J, carbonyl, etc. The following table illustrates such retention enhancing groups.

 In the present invention, an admission enhancing group is a group that binds or connects substitutively, adhesively, cohesively, or in any other way to the AAA (carrying an antibacterial agent) to the oral (ie, teeth and gums) surfaces with an “delivery” of antibacterial agents to these surfaces. Organic retention enhancing groups, usually hydrophobic, are combined or otherwise bound the antibacterial agent to the UAA and thereby promote the retention of the antibacterial agent to the UAA and indirectly on intraoral surfaces. In some cases, the attachment of an antibacterial agent occurs by physical capture of its UAA, especially if a polymer is crosslinked, the structure of which itself creates an increased number of sites for such a capture. The presence of a higher molecular weight, more hydrophobic crosslinking fragment in the crosslinked polymer further promotes the physical uptake of the antibacterial agent and its addition to or incorporation into the polymer UAA.

 It is recommended that the AAA be an anionic polymer consisting of a chain or skeleton comprising repeating units, each of which preferably has at least one carbon atom and preferably at least one directly or indirectly leaving a monovalent receipt enhancing group and at least one directly or an indirectly extending retention enhancing group geminally, vicinally, or, less preferably, in some other way associated with atoms, preferably atoms at leroda chain. It is at least recommended that the polymer contains admission-enhancing groups and / or retention-enhancing groups and / or other divalent atoms or groups in the form of bonds in the polymer chain instead of or in addition to carbon atoms or as crosslinking fragments.

 It must be emphasized that any UAA, given as an example or illustration, not having both enhancing the intake and enhancing the retention of the groups, can and should preferably be chemically modified by known methods to obtain the recommended UAA having both types of groups, preferably a number of such groups , in the case of the recommended polymeric AAA, it is desirable to optimize the substativity and the receipt of the antibacterial agent on the oral surfaces, so that the repeating groups in ve at least 10%, preferably at least 50%, more preferably at least 80% and up to 95% or 100% by weight on the polymer.

которая, однако, не имеет усиливающих удерживание групп. Группы последнего типа присутствуют, однако, в поли(1-фосфонопропене), содержащем звенья формулы

Для применения в настоящем изобретении в качестве УАА, содержащем фосфоновую кислоту, рекомендуется поли(бета-стиролфосфорная кислота), содержащая звенья формулы

где Ph ненил, в которой усиливающая поступление фосфоновая группа и усиливающая удерживание фенильная группа связаны с вицинальными атомами углерода цепи, или сополимер бетастиролфосфоновой кислоты с винилфосфонилхлоридом, в котором звенья формулы III перемежаются или неупорядоченно связаны со звеньями формулы I, или поли(альфа-стиролфосфоновая кислота), содержащая звенья формулы:

в которой группы, усиливающие поступление и удерживание, геминально связаны с цепью.According to a preferred embodiment of the invention, the AAA is a polymer consisting of repeating units in which one or more phosphonic acid-enhancing groups are attached to one or more carbon atoms of the polymer chain. An example of such a UAA is poly) (vinylphosphonic acid containing units of the formula:

which, however, does not have retention enhancing groups. Groups of the latter type are, however, present in poly (1-phosphonopropene) containing units of the formula

For use in the present invention as a AAA containing phosphonic acid, it is recommended that poly (beta-styrene phosphoric acid) containing units of the formula

where Ph is nenyl, in which the phosphonyl group and the retention enhancing phenyl group are bonded to the vicinal carbon atoms of the chain, or a copolymer of betastirolphosphonic acid with vinylphosphonyl chloride, in which the units of formula III are alternated or randomly linked to the units of formula I, or poly (alpha-styrene phosphonate ) containing units of the formula:

in which groups that enhance intake and retention are geminally linked to a chain.

 Such polymers of styrene-phosphonic acid and its copolymers with other inert monomers with ethylene unsaturation usually have a molecular weight in the range of 2000 to 30,000, preferably 2500 to 10000. Inert monomers do not significantly affect the target value of any copolymer used in the invention as an AAA.

поли(аллилбис)фосфоноэтиламин) со звеньями формулы

Другие фосфонированные полимеры, например, поли(аллилфосфоноацетат), фосфонированный полиметакрилат и т. д. а также геминальные дифосфонатные полимеры, описанные в опубликованном европейском патенте N 0321233, могут быть использованы в настоящем изобретении при условии, разумеется, что они содержат или модифицированы, чтобы содержать вышеозначенные органические усиливающие удерживание группы.Other polymers containing a phosphonic acid group include, for example, phosphonated ethylene with units of the formula
- / (CH ₂ ) ₁₄ CHPO ₃ H ₂ / (V)
where it can be, for example, an integer or take values that provide the polymer with a molecular weight of about 3000, poly (butene-4,4-diphosphonate) sodium with units of the formula

poly (allylbis) phosphonoethylamine) with units of the formula

Other phosphonated polymers, for example, poly (allylphosphonoacetate), phosphonated polymethacrylate, etc., as well as geminal diphosphonate polymers described in published European patent N 0321233, can be used in the present invention, provided, of course, that they contain or are modified to contain the aforementioned organic retention enhancing groups.

 In one aspect of the present invention, the oral composition comprises an orally acceptable carrier, an agent effective in enhancing an antibacterial agent with an average molecular weight of 1,000 to 1,000,000, which contains at least one functional group that enhances the intake of the antibacterial agent and at least at least one organic group that enhances the retention of antibacterial agents, and such an agent with these groups essentially does not contain a water-soluble alkali metal and and an ammonium synthetic anionic linear polymeric polycarboxylate salt with a molecular weight of 1000-1000000, the composition also contains a polyphosphate preventing calculus formation, such as a mixture of potassium and sodium salts, the ratio of potassium to sodium in the composition is less than 3: 1, for example, from 0.37 to 1.04 1.

 According to another recommended embodiment of the invention, the AAA contains a synthetic anionic polymer allicarboxylate, which is also an inhibitor of the alkaline phosphatase enzyme. Synthetic anionic polymeric polycarboxylates and their complexes with various cationic bactericides, zinc and magnesium have been previously described as such to prevent the formation of agents, for example, in US Pat. No. 3,429,963 to Shedlovsky, US Pat. No. 4,152,420 to Gabbar, US Pat. No. 3,956,480 to Pichter et al. U.S. Pat. No. 4,138,477 to Gannar; U.S. Pat. No. 4,183,914 to Gabbar, et al. However, only the description corresponding to US Pat. No. 4,627,977 indicates the use of such a polycarboxylate for inhibiting saliva hydrolysis of pyrophosphate preventing calculus formation in combination with a compound giving a source of fluoridion. It is necessary to indicate that the synthetic anionic polymeric polycarboxylates described in the above patents, if they contain or are modified to have enhancing group retention, are applicable in the compositions and methods of the invention as AAA, and the descriptions of these patents in this approach are incorporated by reference.

 Such synthetic anionic polymeric polycarboxylates are often used as free acids, or preferably in the form of partially or more preferably completely neutralized, water-soluble or water-swellable (hydratable, gel-forming) alkali metal (e.g. potassium, preferably sodium) or ammonium salts. Recommended copolymers (1: 4 to 4: 1) of maleic anhydride or maleic acid with another polymerizable monomer with ethylene unsaturation, preferably a methyl vinyl ether-maleic anhydride copolymer with a molecular weight (MV) of 30,000 to 1,000,000. Such copolymers are manufactured by GAF Corporation under the trade name Gantrez, for example: Gantrez A N 139 (MV 5000000), Gantrez 119 (MV 250,000), but especially S-97 Gantrez for pharmaceutical purposes (MV 70,000).

 Other polymeric polycarboxylates useful in the invention as UAA, containing or modified to contain retention enhancing groups, include the polycarboxylates described in US Pat. No. 3,956,480 cited above, such as copolymers of 1: 1 maleic anhydride with ethyl acrylate, hydroxyethyl methacrylate, N-vinyl -2-pyrrolidone or ethylene, the latter being produced, for example, by Monsanto under the designation EMA N 1103 (MV 10000) and EMA C ace 61, as well as copolymers (1: 1) of acrylic acid with methyl or hydroxyethyl methacrylate Methyl or ethyl acrylate, isobutyl vinyl ether or N-vinyl-2-pyrrolidone.

 Additional applicable polymeric polycarboxylates are described in US Pat. Nos. 4,138,477 and 3,4183,914 cited above, and they contain or are modified to contain retention enhancing groups, including copolymers of maleic anhydride with styrene, isobutylene or ethyl vinyl ether, polyacrylic, polyitaconic, and also polymaleic acids oligomers with MB below 1000, supplied under the brand name Uniroal NP-2.

 In general, polymerizable carboxylic acids with ethylene or olefinic unsaturation and a retention enhancing group containing an activated carbon-carbon olefinic double bond and at least one carboxyl, i.e., acids containing an olefinic double bond, are readily realized during polymerization due to it the presence in the molecule of the monomer either in the alpha-beta position with respect to the carboxyl, or as part of the terminal methylene. Examples of such acids include acrylic, methacrylic, ethacrylic, alpha-chloroacrylic, crotonic, beta-acryloxypropionic, sorbic, alpha-chlorosorbic, cinnamic, beta-styrene-acrylic, suconic, itaconic, citraconic, mesaconic, glutaconic, 2-acon, benzyl acrylic, 2-cyclohexyl acrylic, angelic, umbellic, fumaric, maleic acids and anhydrides. Other various olefin monomers copolymerizable with the above carboxylic monomers include vinyl acetate, vinyl chloride, dimethyl maleate, and the like. The copolymers usually contain carboxyl groups in the form of salts in an amount sufficient to impart water solubility to the copolymer.

 The so-called carboxyvinyl polymers described as components of toothpastes in US Pat. No. 3,980,767 to Choron et al. Also apply to the present invention. U.S. Patent 3,935,306 to Ronerts et al. U.S. Patent 3,919,409 to Perla et al. US patent N 3911904 yf bvz Harrions and US patent N 37121604 in the name of C0lodney et al. These polymers are manufactured by VV Goodrich under the brand names Carbapol 934, 940 and 941, and they are a colloidal water-soluble polymer of polyacrylic acid crosslinked with 0.75% 2 polyallylsaccharose or polyallipentaerythrate as a crosslinking agent, such a crosslinked structure and cross-links provide target enhancement retention due to hydrophobicity and / or physical uptake of an antibacterial agent, etc. To some extent, polycarbophil, which is a polyacrylic acid crosslinked less than 2% divinyl glycol, lower amounts, the molecular weight and / or hydrophobicity of which as a crosslinking agent do not provide or provide only a slight retention force. An example of a more effective retention enhancing crosslinking agent is 2,5-dimethyl-1,5-hexadiene.

 The synthetic anionic polymeric polycarboxylate component is most often a hydrocarbon with possible halogen or oxygen-containing substituents and bonds represented, for example, by ester, ether or OH groups, and if present, this component is used in the present compositions in approximate amounts up to 4 wt. (usually at least 0.05%).

 AAA can also include natural anionic polymeric polycarboxylates containing retention enhancing groups. Carboxymethyl cellulose and other binders, resins and film-forming substances that do not have the aforementioned entry-enhancing and / or retention-enhancing groups are not effective as AAA.

As an illustration of the UAA, containing phosphinic and / or sulfonic acid in the form of enhancing the supply, polymers and copolymers containing units or fragments formed during the polymerization of vilyl or alkylphosphinic and / or sulfonic acids, substituted as necessary in 1 or 2, can be mentioned (or 3) a carbon atom with a retention enhancing group, for example, a group of the above formula: - (X) _n -R. Mixtures of such monomers and their copolymers with one or more inert polymerizable ethylene unsaturated monomers of the type described above in relation to the synthetic anionic polymer polycarboxylates used above can be used. As will be noted, in these and other polymeric AAAs useful in the present invention, usually only one acidic acid-enhancing group is associated with any given carbon atom and another polymer backbone atom or branch thereof. Polysiloxanes containing or modified to contain, off-feed and retention-enhancing groups can also be used as AAA in the present invention. As UAA in the present invention, ionomers are used, containing or modified to contain, enhancing the intake and enhancing the retention of the group. Ionomers are described on pages 546-573 of the Encyclopedia of Chemical Technology by Kark Otmer, Third Edition, Supplementary Volume, John Wiley and Sons, Inc. 1984, which is incorporated herein by reference. In addition, in the present invention, the quality of AAA is applicable provided that it contains or is modified to contain retention enhancing groups of polyesters, polyurethanes, artificial or natural polyamides, including proteins and protein compounds such as collagen, poly (argenine) and other polymerized amino acids.

 Upon receipt of an oral preparation by initially dissolving the polyphosphate and antibacterial agent in a moisturizer and surfactant, followed by the gradual addition of UAA to them, especially polycarboxylate, the solution becomes clear and can be described as a “microemulsion”. With an increase in the amount of polycarboxylate so that the complete oral preparation contains at least 2.2 wt. polycarboxylate, the solution becomes cloudy and can be characterized as a "macroemulsion". In compositions such as "macroemulsions" the anti-bacterial action that prevents the formation of plaque is apparently optimal.

 The target ratio by weight of the water-insoluble non-cationic antibacterial agent to the prevention of calculus formation of polyphosphate from more than 0.72: 1 to less than 4: 1, for example from 1: 1 to 3.5: 1, especially from 1.6: 1 to 2, 7: 1.

 In order to optimize the effectiveness against calculus formation of the oral composition, the presence of inhibitors of enzymatic hydrolysis of polyphosphate is desirable. Such inhibitors are used in an amount sufficient to provide a fluoride ion source of 25-5000 ppm fluoride ions and contain up to 3% or more synthetic anionic polymeric polycarboxylate with a molecular weight of 1,000,000,000, preferably 300,000,000,000.

 Sources of fluoride ions or fluoride-supplying components as acid phosphatase and pyrosphatase enzyme inhibitors are well known as anticaries agents. Such compounds may be slightly soluble in water or be completely insoluble in it. The compounds are characterized by the ability to release fluoride ions in water and the inability to enter into undesirable reactions with other compounds of the oral preparation. Such substances include inorganic salts of hydrofluoric acid, such as soluble alkali metal and alkaline earth salts, for example sodium fluoride, potassium fluoride, ammonium fluoride, calcium fluoride, copper fluoride such as copper fluoride (1), zinc fluoride, barium fluoride, fluorosilicate sodium, ammonium fluorosilicate, sodium fluorozirconate, ammonium fluorozirconate, sodium monofluorophosphate, aluminum mono- and difluorophosphate, fluorinated sodium calcium pyrophosphate. Alkali metal and tin fluorides are recommended, such as sodium and tin fluorides (P), sodium monofluorophosphate (MFF), and mixtures thereof.

 The amount of fluorine-containing compound to a certain extent depends on the type of compound, its solubility and the type of oral preparation, but this should be a non-toxic amount, usually 0.005 3% per drug. In a dentifrice such as tooth gel, toothpaste (including tooth cream), tooth powder or dental tablets, the amount of such a compound that releases up to 5000 ppm G-ions by weight should be considered satisfactory. Any acceptable minimum amount of such a compound may be used, but it is recommended that it be used in amounts sufficient to isolate the compound 300 to 2000 ppm, more preferably 800 to 1500 ppm of fluoride ions.

Typically, in the case of alkali metal fluorides, this component is present in an amount of up to 2 wt. based on the weight of the preparation, preferably in the range of 0.05 to 1%. In the case of sodium monofluorophosphate, the compound may be present in an amount of 0.1 to 3%, more typically about 0.76%
In oral formulations such as mouthwashes, lozengis, and chewing gum, the fluorine-supplying compound is usually present in an amount sufficient to release up to 500 ppm by weight of fluoride ion. Usually present 0.005 to 1 wt. such a connection.

 In certain, particularly recommended forms of the invention, the oral composition may be liquid in nature, such as a mouthwash or mouth rinse. In such a preparation, the carrier is usually a water-alcohol mixture, preferably comprising a humectant, as described below. Typically, the ratio by weight of water to alcohol is from 1: 1 to 20: 1, preferably from 3: 1 to 10: 1, and more preferably from 4: 1 to 6: 1. The total amount of water-alcohol mixture in the preparation of this type is usually in the range of 70 to 99.9 wt. on the drug. Ethanol or isopropanol is usually used, of which ethanol is preferred.

 The pH value in such a liquid and other preparations, as a rule, is in the range of 4.5 to 9, usually 5.5 -8. Recommended pH values are 6. 8. It is worth noting that the compositions of the invention can be used at oral pH values below 5 without significant decalcification or other damage to tooth enamel. The pH can be adjusted by adding an acid (e.g. citric or benzoic acid) or a base (e.g. sodium hydroxide) or a buffer (e.g. citrate, benzoate, sodium carbonate or bicarbonate, disodium hydrogen phosphate, sodium hydrogen phosphate, etc.).

In certain other preferred forms of the present invention, the oral composition may be solid or pasty in nature, such as a tooth powder, tooth tablets or a dentifrice such as a toothpaste (tooth cream) or a gel dentifrice. The carrier of such solid or paste preparations typically includes a polishing material acceptable to the teeth. Examples of polishing materials include water-insoluble sodium metaphosphate, potassium metaphosphate, tricalcium phosphate, dehydrated calcium phosphate, anhydrous dicalcium phosphate, calcium pyrophosphate, magnesium orthophosphate, trimagnesium phosphate, calcium carbonate, hydrated alumina, calcined alumina, silicate aluminum silicate, aluminum silicate, mixtures thereof. Other suitable polishing materials include particles of thermosetting resins described in US Pat. No. 3,070,510, issued December 15, 1962, such as melamine, phenol, and urea-formaldehyde resins, as well as crosslinked polyepoxides and polyesters. Recommended polishing materials include crystalline silica with a particle size of about 5 microns, an average particle size of about 1.1 microns and a specific surface area of about 50,000 cm ² / g, silica gel or colloidal silicon oxide and complex amorphous alkali metal aluminosilicates.

 In the case of using visually transparent gels as polishing agents, colloidal silicon oxide such as that sold under the brand name SILOID, for example Siloid 72 and Siloid 73, is particularly useful. or the brand name SANTOGEL, for example Santogel 100, as well as alkali metal aluminosilicate complexes, since their refractive indices are close to the refractive indices of gel-forming liquid-liquid systems (including water and / or a moisturizer) commonly used in dentifrices.

 Many of the so-called "Water-insoluble" polishing materials are anions in nature and include a small amount of soluble product. Thus, insoluble sodium metaphosphate can be obtained by any suitable method, for example, as described in the Thorpe Dictionary of Applied Chemistry, Volume 9, 4th edition, p. 510 511. Modifications of insoluble sodium metaphosphate, known under the names Madrell salt and Currol salt, are additional examples of acceptable materials. Such metaphosphate salts have only insignificant solubility in water, as a result of which they are usually caused by insoluble metaphosphates (NMFs). Impurity IMP contains small amounts of soluble phosphate, usually within a few percent, for example, up to 4 wt%. The amount of soluble phosphate, which is believed to be soluble sodium trimetaphosphate in the case of insoluble metaphosphate, can be reduced up to complete removal by washing if desired water. Insoluble alkali metal metaphosphate is usually used in the form of a powder with a particle size such that not more than 1% of the material has a particle size above 37 microns.

 Polishing material is usually present in a solid or pasty composition in a concentration by weight of 10 99%. Recommended concentrations are 10 75% for toothpaste and 70 99% for tooth powder. In toothpastes, if a silicon-containing compound is used as a polishing material, it is usually present in an amount of 10-30 wt%. Other polishing materials are typically present in an amount of 30 75 wt.

 In a toothpaste, a liquid carrier may include water and a humectant, typically in the range of 10 to 80 wt. on the drug. Examples of suitable humectants / carriers include glycerin, propylene glycol, sorbitol, and polypropylene glycol. Also promising are liquid mixtures of water, glycerin and sorbitol. In transparent gels, for which the refractive index is of particular importance, it is recommended to use 2.5 to 30 wt. water, 0 70 wt. glycerol and 20 to 80 wt. sorbitol.

Toothpastes, creams and gels usually contain a natural or synthetic thickener or gel-forming agent, usually in an amount of 0.2 to 10, preferably 0.5 to 5 wt. Suitable thickeners are synthetic hectorite, synthetic colloidal clay, which is a complex of magnesium silicate and an alkali metal, and manufactured, for example, by Laport Industries Limited under the brand name Laponite (e.g. Laponite SR, SP 2002 D). Analysis of Laponite D shows the following approximate content of components, wt. 58 SiO ₂ ; 25.4 MgO; 3.05 Na ₂ ; 0.98 Li ₂ O, some water and traces of other metals. Its true specific gravity is 2.53 and its apparent bulk density (g / ml at 8% humidity) 1.

 Other suitable thickeners include Irish moss, iota-carrageenan, tragacanth gum, starch, polyvinylporrolidone, hydroxyethylpropyl cellulose, hydroxybutyl methyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose such as nitroalkylmethoxymethoxymethoxymethoxylate, 4-methylmethoxymethoxymethoxymethoxylate, amethoxymethoxymethoxymethoxylate )). In some dentifrice obtained in accordance with the present invention, especially in the presence of more than 0.35 wt. water-insoluble antibacterial agent and the presence of a silicon-containing polishing agent in an amount of less than 30 wt. the inclusion of a substance that dissolves the antibacterial agent may be desirable. Such solubilizers include moisturizing polyols such as propylene glycol, dipropylene glycol and hexylene glycol, cellosolves such as methyl cellosolve and ethyl cellosol, vegetable oils and waxes containing at least 12 carbon atoms and a straight chain such as olive oil, castor oil and petrolatum, as well as esters such as amyl acetate, ethyl acetate and benzyl benzoate.

 It must be indicated that, as is customary, oral preparations must be sold or otherwise distributed in packages with appropriate labels. So, a vessel with a mouthwash should have a label describing the composition, method of use for rinsing or rinsing the mouth, and toothpaste, cream or gel should be contained in wrinkled tubes usually made of aluminum, lined lead or plastic, or contained in compressible, injected or pressurized dispersants measuring the contents and having labels characterizing the component composition of the toothpaste, gel or tooth cream.

 Organic surfactants are used in the compositions of the present invention to achieve an enhanced prophylactic effect, to facilitate the complete distribution in the oral cavity of an anti-calculus agent, and to prevent the formation of plaque, and to make the present compositions more cosmetically acceptable. Organic surfactants are inherently preferred, preferably anionic, nonionic or ampholytic, and detergents are recommended as surfactants to impart detergent and foaming properties to the composition. Suitable examples of anionic surfactants include water-soluble salts of monosulfates of monoglycerides of higher fatty acids, such as the sodium salt of monosulfonated monoglyceride of fatty acids of hydrogenated coconut oil, higher alkyl sulfates such as sodium lauryl sulfate, alkyl aryl sulfates, alkyl aryl sulfonate sulfonates, , 2 dihydroxypropanesulfonate and saturated higher aliphatic acylamides of lower aliphatic aminocarbons acids such as those having 12 to 16 carbon atoms in a fatty acid, alkyl or acyl radical, etc. Examples of the latter amides are N-lauroylsarcosine, as well as the sodium, potassium and ethanolamine salts of N-lauroyl, N-myristoyl or N- palmitoylsarcosine, which should not contain soaps and similar derivatives of higher fatty acids. The use of these sarcosinates in the oral compositions of the present invention is particularly promising, since these substances exhibit a long and noticeable effect on the inhibition of acid formation in the oral cavity, associated with the decomposition of hydrocarbons, and also slightly reduce the solubility of tooth enamel in acid solutions. Examples of water-soluble non-ionic surfactants include the condensation products of ethylene oxide with various compounds reacting with it having an active hydrogen atom and long hydrophobic (for example, aliphatic chains with 12 to 20 carbon atoms), and such condensation products ("ethoxamers") contain hydrophilic polyoxyethylene moieties, including condensation products of poly (ethylene oxide) with fatty acids, fatty alcohols, fatty amides, polyhydric alcohols (e.g. sorbitan monostearate) and polypropyleneoxy ohms (e.g., pluronic agent).

 Surfactants are usually present in an amount of 0.1 -5 wt. preferably 1 2.5%. It should be noted that surfactants help to dissolve the non-cationic antibacterial agent and thereby reduce the required amount of solubilizing moisturizer.

 Various other substances, such as brighteners, preservatives, silicones, chlorophyll compounds and / or ammonium-containing compounds, for example, urea, diammonium phosphate and mixtures thereof, can also be incorporated into the oral preparations of the present invention. Such auxiliary substances, if present, are introduced into the preparations in amounts that do not undesirably affect the target properties and parameters. It is necessary to avoid the presence of significant amounts of salts of zinc, magnesium and other metals, usually soluble, capable of forming complexes with the active components of the present invention.

 Any suitable flavoring and sweetening agents may be used. Examples of suitable flavoring components include flavoring oils, for example, peppermint, peppermint, screw oil, sassofras oil, clove oil, sage oil, eucalyptus oil, marjoram oil, cinnamon oil, lemon oil and orange oil, as well as methyl salicylate. Suitable sweeteners include sucrose, lactose, maltose, sorbitol, xylitol, sodium cyclamate, perillartine, aspartyl phenylalanine methyl ester (AMP), saccharin, etc. It is desirable that the flavoring and sweeteners are individually or together present in an amount of 0.1 to 5 % or more per drug. Moreover, aromatic oil, apparently, helps to dissolve the antibacterial agent.

 In the recommended practice of the present invention, the oral composition of the invention, for example, in the form of a mouthwash or a dentifrice containing the composition of the invention, is applied regularly to the tooth enamel, for example, daily or every second or third day, or preferably 1-3 times per day at a pH of 4.5 to 9, typically 5.5 to 8, preferably 6 to 8, for at least 2 weeks and up to 8 weeks or throughout life.

 The compositions of the present invention can be incorporated into losings, chewing gum or other products, for example, by mixing with a heated rubber base or by applying a rubber base to the outer surfaces, which can be illustrated as gelutong, rubber latex, vinyl resin, etc. preferably with conventional plasticizers and softeners, sugar, or other sweeteners, such as glucose, sorbitol, etc.

 The following examples continue to illustrate the nature of the present invention, but it should be pointed out that the invention is not limited to them. All quantities shown are based on weight, unless otherwise indicated.

 In the following examples, tricolzane (2,4,4'-trichloro-2'-hydroxyphenyl ether) is abbreviated as "TCHE", sodium lauryl sulfate is abbreviated as "NLS", a copolymer of maleic anhydride with methyl vinyl ether manufactured by GAF Corporation under the trade name "Gantrez S 97 "is simply designated as" Gantrez, "tetrasodium pyrophosphate is referred to simply as" pyrophosphate, "and sodium fluoride is designated as" NaF. "

 Example 1. The effectiveness of adsorption and excretion by a tooth mineral of an anti-plaque agent / anti-tartar agent is determined by the adsorption of an antibacterial agent by saliva covering the disks from the tooth mineral (hydroxyapatite) in the presence of pyrophosphate and various amounts of polycarboxylate.

Examine the toothpastes of the following compositions (see table 1)
Gantrez is present in terms of dry matter in an amount of 2.5 parts in toothpaste A and 2 parts in toothpaste B.

To highlight the receipt of an antibacterial agent in the saliva covering the disks made of hydroxyapatite, hydroxyapatite (HA) manufactured by Monsanto Co. washed intensively with distilled water, collected by vacuum filtration and left to crosslink for a day at 37 ^o C. Dried HA grind into powder with a pestle in a mortar. 150 mg of HA was placed in a KBr tablet compression chamber (Barnes Analytical, Syanbord, CT) and pressed for 6 minutes under 10,000 pounds in a Caroer laboratory press. The resulting 13 mm discs are sintered for 4 hours at 800 ^{° C.} in a Thermolyne furnace. Parafilm-stimulated hollow saliva is collected in an ice-cooled glass bottle. The saliva is clarified by centrifugation at 15,000 x g (multiple gravity) for 15 min at 4 ^o C. Sterilization of clarified saliva is carried out at 4 ^o C and stirring by irradiating the sample for 1 hour with UV radiation.

Each fused disk is hydrogenated with sterile water in a polyethylene test tube. Then the water is removed and 2 ml of saliva is replaced. A thin film of saliva is formed by incubating the disk for a day at 37 ^° C. and continuously shaking in a water bath. After this treatment, the saliva is removed and the discs are treated with 1 ml of a solution containing an antibacterial agent (triclosan) in the liquid phase of the dentifrice solution and incubated at 27 ^° C. with continuous shaking in a water bath. After 30 minutes, the disk is transferred to another tube, 5 ml of water is added, after which the disk is gently shaken with a swirl. Then the disk is transferred to a new tube and the washing procedure is repeated twice. Finally, the disc is carefully transferred to a new tube so as to avoid the joint transfer of any liquid along with the disc. After this, 1 ml of methanol is added and the disk is vigorously shaken with a swirl. The sample is left for 30 minutes at room temperature in order to extract adsorption triclosan with methanol. The methanol is purged and clarified by centrifugation in a Beckman PP microcentrifuge at a speed of 10,000 rpm for 5 minutes. After this treatment, methanol is transferred into vessels for high performance liquid chromatography (HPLC) in order to determine the concentration of the antibacterial agent. In all experiments, samples were duplicated twice.

 Table 2 summarizes the data obtained.

 The above data show that with an increase in the amount of Gantrez (toothpaste A), the intake of TCEE in saliva covering the mineral of teeth increases significantly.

Example 2. The following toothpaste is an example of an effective anti-plaque and calculus composition. Parts by weight
Sorbitol (70%) 22.00
Irish Moss 1.00
Sodium hydroxide (50%) 1.00
Gantrez (13, 0.2% solution) 19.00
Water (deionized) 2.60
Sodium Monofluorophosphate 0.76
Sodium Sarin 0.30
Pyrophosphate 2.00
Hydrated Alumina 48.00
Flavoring Oil 0.95
TCGE 0.30
NLS 2.00
Example 3

Mouthwash Parts
Tetrasodium pyrophosphate 2.00
Dumbbell S-97 2.50
Glycerin 10.00
Sodium Fluoride 0.05
Nitriyl lauryl sulfate 0.20
TCGE 0.06
Flavoring Oil 0.40
Water the rest is up to 100
Example 4. Lojingis
75 80% sugar
1 20% cereal syrup
0.1 1% flavoring oil
2% tetrasodium pyrophosphate
2.5% Gantrez S-97
0.01-0.05%
0.01 0.1 TCGE
1-5% magnesium stearate as a lubricant
0.01 0.2% water.

 Example 5

Chewing Gum Parts
Rubber base 25.00
Sorbitol (70%) 17.00
TCGE 0.5 0.1
Tetrasodium pyrophosphate 2.00
Dumbbell S-97 2.50
In one embodiment of the above examples, the S-97 gantrez may be omitted.

 Example 6

Chewing Gum Parts
Rubber base 30.00
TCGE 0.50
Gantrez 2.00
NaF 0.05
Glycerin 0.50
Crystalline Sorbitol 53.00
Tetrasodium pyrophosphate 2.00
Flavoring Oil or Water the rest is up to 100
In the above examples, improved results are also achieved by replacing TCHE with phenol, 2,2'-methylenebis (4-chloro-6-bromophenol), eugenol and thymol and / or when replacing the Gantrez with another UAA such as Carbopolis (e.g. Carbopol 934) or polymers of styrene phosphonic acid with a molecular weight of 3,000 10,000, such as poly (beta-styrene phosphonic acid), copolymers of vinyl phosphonic acid with beta-styrene phosphonic acid and poly (alpha-styrene phosphonic acid), sulfoacrylic oligomers or maleic acrylate maleic acid anhydride copolymer.

 Similar results are achieved when replacing pyrophosphate (tetrasodium pyrophosphate) with a mixture of tetrasodium pyrophosphate and tetracal pyrophosphate with a ratio by weight of potassium to sodium a) 0.37: 1, B) 1.04: 1 and c) 3.5: 1.

 The invention has been described in terms of certain preferred embodiments, but it must be emphasized that modifications and modifications obvious to those skilled in the art should be included within the scope of this application and the scope of the appended claims.

Claims (19)

 1. A dentifrice containing halogenated diphenyl ether, a polishing agent, a thickening agent, a carrier, a polyphosphate salt, characterized in that it further comprises an agent that enhances the antibacterial effect of the agent in the following quantitative ratio of components, wt. Thickener 0.1 10.0
Polishing Agent 10.0 75.0
Polyphosphate salt 0.1 3.0
Halogenated Diphenyl Ether 0.01 5.0
Antibacterial enhancing agent 0.05 4.0
Media Else
the ratio of the agent that enhances the antibacterial effect to the polyphosphate ion is 1.6 1 2.7 1.  2. The tool according to claim 1, characterized in that the carrier includes water, glycerin, sorbitol, propylene glycol.  3. The tool according to claim 1, characterized in that the thickening agent is a synthetic colloidal magnesium-alkali metal-silicate complex clay, Irish moss, iota corragenan, tragacanth resin, starch, polyvinylpyrrolidone, hydroxyethyl propyl cellulose, hydroxyethyl cellulose, silicon carbide di-sodium .  4. The tool according to claim 1, characterized in that as a polishing agent, water-insoluble sodium metaphosphate, calcium metaphosphate, potassium metaphosphate, tricalcium phosphate, dehydrated calcium phosphate, anhydrous dicalcium phosphate, calcium pyrophosphate, magnesium orthophosphate, trimagnesium phosphate, calcium carbonate are used. hydrated alumina, calcined alumina, aluminum silicate, silica, bentonite or thermosetting resins.  5. The tool according to claim 1, characterized in that 2,4,4'-trichloro-2'-hydroxydiphenyl ether is used as the halogenated diphenyl ether.  6. The tool according to claim 1, characterized in that tetrasodium pyrophosphate is used as the polyphosphate salt.  7. The tool according to claim 1, characterized in that the ratio of the agent that enhances the antibacterial effect to the polyphosphate ion is 1.7: 1, 2.3: 1.  8. The tool according to claim 1, characterized in that the agent enhancing the action of the antibacterial agent is an anionic polymer having a number of groups that enhance the intake and organic groups that enhance the retention.  9. The tool according to claims 1 and 8, characterized in that the anionic polymer is a chain of repeating units, each of which consists of at least one carbon atom.  10. The tool according to claims 1 and 9, characterized in that each link contains at least one reinforcing receipt group and at least one organic holding reinforcing group attached to the same or official or other chain atoms.  11. The tool according to claims 1 and 10, characterized in that the gain-enhancing group is carboxyl or its salt.  12. The tool according to claims 1, 10 and 11, characterized in that the agent that enhances the action of the antibacterial agent is a copolymer of maleic acid or maleic anhydride with another polymerizable monomer with ethylene unsaturation or its salt.  13. The tool no PP.1, 10 12, characterized in that the other monomer is methyl vinyl ether in the ratio of 4: 1 1: 4 to maleic acid or maleic anhydride.  14. The tool according to claims 1, 10 13, characterized in that the molecular weight of the copolymer is 30,000 to 100,000.  15. The tool according to paragraphs. 1, 10 14, characterized in that the average molecular weight of the copolymer is about 70,000.  16. The tool according to claims 1, 10 15, characterized in that the income-enhancing group is a phosphonic group or its salt.  17. The tool according to claims 1, 10 16, characterized in that the agent that enhances the action of the antibacterial agent is a poly (beta-styrene-phosphonic) acid, poly (alpha-styrene-phosphonic) acid or a copolymer of one styrene-phosphonic acid with another, or other inert polymerizable monomers with ethylene unsaturation or their salts.  18. The tool according to paragraphs. 1, 10 17, characterized in that the agent that enhances the action of the antibacterial agent has a mol.m. 1000 30000.  19. The tool according to paragraphs. 1, 10 18, characterized in that it contains a source supplying fluoridions.

Images